Microsoft powerpoint - 9-10 pardi [compatibility mode]
*This program is supported by Salix. Neither Mayo
• Microscopic colitis used as umbrella term
-subsets collagenous, lymphocytic colitis
• Unclear if distinct or parts of a spectrum
Which of the following is true regarding patients with microscopic colitis? A) Abdominal pain is uncommon B) Weight loss is uncommon C) Fecal leukocytes are uncommon D) Most meet Rome criteria for IBS Which of the following is true regarding patients with microscopic colitis? A) Abdominal pain is uncommon B) Weight loss is uncommon C) Fecal leukocytes are uncommon D) Most meet Rome criteria for IBS
• Constant or intermittent watery diarrhea
• 50% with abdominal pain, mild weight loss
• Arthralgias, autoimmune disorders, sprue
– 28-65% in secondary analysis of RCTs2
1) Limsui IBD 2007 2) Madish World J Gastro 2005
• Association with NSAIDs and other meds
Which of the following is true regarding the epidemiology of microscopic colitis? A) Incidence less common t Crohn’s B) It is about as common as IBS C) The incidence incidence is increasing significantly D) It accounts for 30-40% of watery diarrhea Which of the following is true regarding the epidemiology of microscopic colitis? A) Incidence less common t Crohn’s B) It is about as common as IBS C) The incidence incidence is increasing significantly D) It accounts for 30-40% of watery diarrhea
• Female predominance (CC>LC in most)
1998-2001
• NSAIDs and other drugs
• Abnormal fluid/salt secretion/absorption
• Abnormal collagen synthesis/degradation
– acarbose, aspirin, NSAIDs, PPI, SSRI,
The best treatment for severe microscopic colitis is: A) Loperamide B) 5-aminosalicylate C) Budesonide D) Prednisone E) Azathioprine The best treatment for severe microscopic colitis is: A) Loperamide B) 5-aminosalicylate C) Budesonide D) Prednisone E) Azathioprine
• Consider drug-induced microscopic colitis
– If any doubt, stop drug and observe diarrhea
1) Baert, Gastro 2002 2) Miehlke, Gastro 2002 3) Bonderup, Gut 2003 4) Miehlke, DDW 2007
During 16 month median f/u of a budesonide RCT coh
• 34 pts, 9 mg/d x 6 wks, remission 87%
• Relapse: 23% budesonide, 88% placebo
• Relapse: 13% budesonide, 61% placebo
• Relapse 25%, all successfully retreated
• Remission 85% in LC (+ or – cholest.)
1) Pardi Am J Gastro 20022) Olesen Gut 20043) Bohr Gut 1996
• BSS: N=12, response 92%; mean time to response 2
• Mesalamine: N=81, ~3 gm/d, response
• AZA: N=9, steroid refractory or dependent; response
• Methotrexate: N = 19, 7.5-10 mg PO QWk; response
‘good’ in 74%, ‘partial’ in 11% 6
1) Fine, Gastro 1998 2) Fernandez-Banares, AJG 20033) Pardi, Gastro 2001 4) Riddell, J Gastro Hep 2007
Recommended Treatment Approach D/C NSAIDs, other drugs, dairy products tidiarrhea Bismuth subsalicylate Cholestyramine Budesonide Aminosalicylates Prednisone Azathioprine / 6-MP CP999375-2
Microscopic colitis is relatively common cause of diarrhea
Consider celiac disease if suggestion of steatorrhea or
XV LEGISLATURA — ALLEGATO B AI RESOCONTI — SEDUTA DEL 18 DICEMBRE 2007Voghera per verificare se esista compati-bilita` tra il dirigente scolastico e l’am-rezza di un farmaco che non c’e` », pub-biente in particolare con gli enti locali;blicato sul bollettino Aifa n. 4 del 2007allo scopo di offrire « un aggiornamentodettagliato su questa molecola » presentaRubiconto e` il dirigent
Deutsche Bezeichnung Nom français Nome italiano Screening Dépistages de base Screening Allergènes d'Inhalation (d1, e1, e5, g6, g6, g12, t3, w6, d1, e1, e5, m2 Arzneimittel Médicaments Arzneimittel - Allergenkomponenten Médicaments - Composants Farmaci - Component allergenici nur für Forschungszwecke allergéniques pour la recherche soltanto per la ric